Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer
Our preliminary findings suggest that the ErbB pathway may serve as a clinically significant resistance mechanism to intravesical IFNα gene therapy, and when targeted concurrently, may improve treatment efficacy.
Authors
- I-Y. Lee
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Eastern Finland (FI)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- University of Rochester Medical Center (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-26
- DOI
- https://doi.org/10.64898/2026.01.23.701130
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute